Skip to main content

Table 3 Deterministic, sensitivity and threshold results of the model for [68Ga]Ga-PSMA-11 PET/CT versus standard of care

From: Cost-effectiveness of the implementation of [68Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging

 

Incremental cost (€)

Incremental quality of life (QALY)

ICER (€/QALY)

Life years (years)

Net Monetary Benefit*

Incremental treatment cost (€) **

Incremental treatment quality of life (QALY) **

Standard of care (ePLND)***

€ 35,659

10.271

 

15.25

 

€15,586

− 0.07

Strategy

PSMA PET/CT ([68Ga]Ga-PSMA-11 PET/CT)

− € 674

 − 0.011

€58,825

- 0.02

− € 243

− € 757

 + 0.006

Threshold analysis

N1ext by [68Ga]Ga-PSMA-11 PET/CT (FP) = 0.8%

− € 631

0.0003

Dominant

− 0.005

€ 654

− € 656

 + 0.005

ePLND disutility = 0.052

− € 674

0.0002

Dominant

− 0.018

€ 694

− € 757

 + 0.018

  1. *Net monetary benefit was calculated using a willingness to pay of €80,000 per QALY, for both increase and decrease of quality of life. ePLND extended pelvic lymph node dissection, FP false positive, ICER Incremental cost-effectiveness ratio, IKNL  the Netherlands Comprehensive Cancer Organisation, PET/CT  positron emission tomography/computed tomography, PSMA  prostate specific membrane antigen, QALY quality-adjusted life years.
  2. **Results from the decision table for treatment costs and effects
  3. ***For standard of care, the absolute costs and effects are shown